No-Cost, No-Obligation Zantac Cancer Attorney Case Review

Antacid Cancer Attorney
Zantac Lawsuit News

Administrative Procedures Organized in Lawsuits That Claim Zantac Caused Cancer

Thousands of plaintiffs may file lawsuits against Sanofi when informed of the results of the first bellwether trial

Monday, September 28, 2020 - In a recent development regarding the first Zantac cancer trial, a federal judge has organized a group of attorneys to lead 230 plaintiffs. South Florida Caribean News reported; "The team comprises co-lead counsels, the plaintiff's liaison counsel, the plaintiff's steering committee, and a leadership development committee. The court hopes that the team will count on its diversity as the case goes forward." The attorneys are "a diverse group of minorities," both men and women, young and old with the intent of reflecting the diversity of the pool of plaintiffs. The judge hopes that the team will bring a combination of youth and experience to the proceedings as well.

Zantac is Sanofi's flagship medicine and the world's best-selling heartburn and acid reflux reliever. In February of 2020, the company was accused by plaintiffs organized into multidistrict litigation (MDL) in the Southern District of Florida, of concealing the carcinogenic nature of Zantac, (ranitidine). Before its company and FDA recall in early 2020, Zantac was used by over 15 million people every year and earned the company over one billion dollars in profits. Zantac (ranitidine) is sold over the counter and prescribed by doctors. Zantac is an H2 blocker drug. Patient.Info explains, "H2 blockers are a group of medicines that reduce the amount of acid produced by the cells in the lining of the stomach. They are also called 'histamine H2-receptor antagonists' but are commonly called H2 blockers. They include cimetidine, famotidine, nizatidine, and ranitidine (Zantac), and have various brand names."

Online drug testing pharmacy Valisure found Zantac to contain levels of NDMA, a well-known carcinogen that was unacceptably high and likely to cause cancer. Valisure found levels of NDMA thousands of times greater than the 96 ng per tablet that the FDA used as an acceptable benchmark. Valisure filed a citizen petition immediately with the FDA demanding the drug ranitidine be recalled from the market. Sanofi immediately withdrew Zantac and the FDA followed suit on April 1, 2020, to include all manufacturers of ranitidine to recall the drug as well.

Personal lawsuits accuse the Sanofi, the maker of Zantac, of having the responsibility to know and to inform their consumers of the cancer risks of ranitidine. Zantac is accused of causing a variety of cancers with the list growing every day. At last count, lawsuits have been filed that claim using Zantac has caused cancer of the stomach, bladder, esophagus, prostate, colon, intestinal, and breast. Regular Zantac users that have been diagnosed with cancer are urged to seek counsel from a Zantac Cancer Lawyer to see if they qualify to file a claim. Individual cases are being in the process of being organized into groups called multidistrict litigation (MDL) to streamline administrative court proceedings and also to ferret out the facts about the complex science regarding NDMA and Zantac causing cancer for which they are accused.

More Recent Heartburn MedicineLawsuit News:

Lawyers for Zantac Heartburn Medicine Lawsuits

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.

Privacy Notice: This site uses cookies for advertising, analytics and to improve our site services. By continuing to use our site, you agree to our use of cookies. For more information, see our cookie and privacy policy.